Entry of tromethamine into the cerebrospinal fluid of humans after cerebrovascular events

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 1, 1999, Pages 25-32

  Roland, Nau ^a,b   Desel, Herbert ^a   Lassek, Christoph ^a   Kolenda, Herbert ^a   Prange, Hilmar ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PROTEIN; TROMETAMOL;

ADULT; AGED; ANASTOMOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN EDEMA; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PH; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; BLOOD-BRAIN BARRIER; BRAIN EDEMA; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACRANIAL PRESSURE; MALE; MIDDLE AGED; TROMETHAMINE;

EID: 0032807935     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70050-0     Document Type: Article

References (22)

1. 1. Enevoldsen EM, Cold G, Jensen FT, Malmros R. Dynamic changes in regional CBF, intravetitricular pressure, CSF pH and lactate levels during the acute phase of head injury. J Neurosurg 1976;44:191-214.
2. 2. Rosner MJ, Becker DP. Experimental brain injury: successful therapy with the weak base, tromethamine. With an overview of CNS acidosis. J Neurosurg 1984;60:961-71.
3. 3. Brasch H, Thies E, Iven H. Pharmacokinetics of TRIS(hydroxymethyl)-aminornethane in healthy subjects and in patients with metabolic acidosis. Eur J Clin Pharmacol 1982;22:257-64.
4. 4. Pfenninger E, Lindner KH, Ahnefeld FW. Die Infusion von THAM (Trishydroxymelhylaminomethan) als Therapie zur Senkung des erhöhten intrakraniellen Druckes beim akuten Schädel-Him-Trauma. Anaesthesist 1989;38:189-92.
5. 14C-THAM in various rat tissues. Arch Int Pharmacodyn Ther 1971;190: 267-77.
6. 14 labeled tris (hydroxymethyl) aminomethane. Am J Physiol 1962;202:1011-4.
7. 7. Robin ED, Wilson RJ, Bromberg PA. Intracellular acid-base relations and intracellular buffers. Ann NY Acad Sci 1961;92:539-46.
8. 8. Wolf AL, Levi L, Marmarou A, Ward JD, Muizelaar PJ, Choi S, et al. Effect of THAM upon outcome in severe head injury: a randomised prospective clinical trial. J Neurosurg 1993;78:54-9.
9. 9. Wiklund L, Sahlin K. Induction and treatment of metabolic aeidosis: a study of pH changes in porcine skeletal muscle and cerebrospinal fluid. Crit Care Med 1985;13:109-13.
10. 10. Sawchuk RJ, Hedaya MA. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid; I: effect of probenecid. Pharm Res 1990;7:332-8.
11. 11. Nau R, Zysk G, Thiel A, Prange HW, Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man. Eur J Clin Pharmacol 1993;45:469-75.
12. 12. Nau R, Kinzig-Schippers M, Sorget F, Schinschke S, Rössing R, Müller C, et al. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Antimicrob Agents Chemother 1997; 41:987-91.
13. 13. Nau R, Prange HW, Kinzig M, Frank A, Dressel A, Scholz P, et al. Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies. Antimicrob Agents Chemother 1996;40:763-6.
14. 14. Nau R, Prins FJ, Kolenda H, Prange HW. Temporary reversal of serum to cerebrospinal fluid glycerol concentration gradient after intravenous infusion of glycerol. Eur J Clin Pharmacol 1992;42:181-5.
15. 15. Nau R, Desel H, Lassek C, Thiel A, Schinschkc S, Rössing R, et al. Slow elimination of mannitol from human cerebrospinal fluid. Eur J Clin Pharmacol 1997; 53:271-4.
16. 16. Nau R, Sörgel F, Prange HW. Lipophilicity at pH 7.4 and molecular size govern the entry of not actively transported drugs into the cerebrospinal fluid in humans with uninflamed meninges. J Neurol Sci 1994;122:61-5.
17. 17. Tochino Y, Schanker LS. Active transport of quarternary ammonium compounds by the choroid plexus in vitro. Am J Physiol 1965;208:666-73.
18. 18. Davson H, Welch K, Segal MB. Physiology and pathophysiology of the cerebrospinal fluid. Edinburgh: Churchill Livingstone; 1987.
19. 19. Nau R, Prange HW. Estimation of steady state antibiotic concentration in cerebrospinal fluid from single-dose kinetics. Eur J Clin Pharmaeol 1996;49:407-9.
20. 20. Kaufmann GE, Cardoso ER. Aggravation of vasogenic cerebral edema by multiple-dose mannitol. J Neurosurg 1992;77:584-9.
21. 14-labelled mannitol from serum into cerebrospinal fluid and brain. Exp Neurol 1964;10:264-70.
22. 22. Hartmann A, Stingele R, Schnitzler M. General treatment strategies for elevated intracerebral pressure. In: Hacke W, Hanley DF, Einhäupl KM, Bleck TP, Diringer MN, Ropper AH, editors. Neurocritical care. Berlin: Springer; 1994. p. 101-15.